Multidrug resistance (MDR) to chemotherapeutic drugs is the main cause of chemotherapy
failure in cancer treatment, and it generally results from expression of ATP-dependent efflux …

Overexpression of ATP-dependent efflux pump P-glycoprotein (P-gp) is the main cause of
multidrug resistance (MDR) and chemotherapy failure in cancer treatment. Inhibition of P-gp …

Abstract P-glycoprotein (P-gp) pumps multiple types of drugs out of the cell, using energy
generated from ATP, and confers multidrug resistance (MDR) on cancer cells. ZD6474 is an …

Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug
resistance (MDR). This protein acts as an energy-dependent drug efflux pump reducing the …

Purpose H1 is a novel derivative of tetrandrine (Tet). Here we investigate the ability of H1 to
reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR) and its mechanisms …

Overexpression of p-glycoprotein (p-gp) leads to the production of multi-drug resistance
(MDR) which could discharge various anti-tumor chemicals with structural heterogeneity …

Multidrug resistance is a serious problem and a common cause of cancer treatment failure,
leading to patient death. Although numerous reversal resistance inhibitors have been …

Targeted inhibition of a drug efflux transporter P-glycoprotein (P-gp) is an important strategy
to reverse multidrug resistance in cancer chemotherapy. In this study, a rationally structural …

Abstract P-glycoprotein (P-gp) mediated multidrug resistance (MDR) is one of the main
obstacles in tumour chemotherapy. A promising approach to reverse MDR is the combined …